Scholar Rock Holding Corporation - Common Stock (SRRK)

The market was hoping the company could better contain its losses.

Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027.

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Jefferies thinks big pharma companies are "still on the hunt" for deals.

Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy and safety in SMA treatment.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.